InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection (Brazil Cohort)
Status:
Recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
Comparison of the effects of CYT107 vs Placebo administered by intra-muscular route (IM) at
10μg/kg twice a week for three weeks on immune reconstitution of lymphopenic COVID-19
patients